Tukysa Availabtlity in India

• AVAILABILITY IN MAHARASHTRA

Tukysa has an active pharmaceutical ingredient, tucatinib, which is potently used to treat adult patients with HER2-positive breast cancer in combination with some other drugs. It is not known if Tukysa is safe and effective for children. Before taking Tukysa, it is important to tell the healthcare provider about any liver problem or pregnancy, as it can cause hypersensitivity and harm to the fetus. It is available in Maharashtra, and the cost of Tuksya in Mumbai is pocket efficient.

While taking the drug, it is advised to patients to swallow Tukysa tablets whole and not to chew, crush, or split them before swallowing. If the tablet is broken, cracked, or not otherwise intact, it is advised not to use it and discard it immediately. Patients are advised to take Tukysa approximately 12 hours apart and at the same time each day, with or without a meal. If the patient vomits or misses a dose of Tukysa, it is instructed to take the next dose at its usual scheduled time. When Tukysa is given in combination, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily, taken within 30 minutes after a meal. Capecitabine and Tukysa can be taken at the same time. 

You can readily purchase this drug at cheaper rates as the cost of Tucatinib in Noida is 

much more reasonable and pocket efficient.

• USE IN SPECIFIC POPULATION

1. Pregnancy- 

As shown in some animal studies and the method of action of tucatinib, it is found that it can potentially cause fetal harm if taken by pregnant women. So it is advised not to take it by a pregnant woman, and always tell the healthcare provider if you are pregnant before starting the treatment.

Lactation-

There is no such data on the presence of tucatinib in milk. Metabolites of TUKSYA in human milk or their effects on the breastfed child or milk production still need to be discovered as there are no studies present to show it. But because of the potential for serious adverse reactions in breastfed children, it is advised not to breastfeed.

For further information about the use of the drug in a specific population and Tukysa cost in India, you can visit us at https://www.indianpharmanetwork.in/

• COMPOSITION

The active ingredient of Tukysa is tucatinib, and the list of inactive ingredients contains copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose in tablet core. In Tukysa tablet coating, a yellow film coat is made up of polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated. It is to note that the use of Tukysa in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment because, in the case of patients with severe renal impairment, capecitabine is contraindicated. 

• DESCRIPTION

Tucatinib is a kinase inhibitor. The molecular weight of Tucatinib is 480.52 g/mol. Tucatinib is supplied as 50 mg and 150 mg film-coated tablets for oral use. Each Tukysa 50 mg tablet contains potassium and sodium. To know more about Tukysa tablets cost, you can visit us at Indian Pharma Network; we will be happy to help you. 

• INDIAN PHARMA NETWORK

This medicine is under additional monitoring, which states that it is monitored even more intensively than other medicines. As it is therapeutically used in Breast Neoplasms and Neoplasm Metastasis, it requires extensive care. This drug has been shown to improve the length of time patients with advanced or metastatic HER2-positive breast cancer lived without their disease worsening.

You can get this drug under a prescription and from an authorized dealer. Indian Pharma Network is among the certified dealers and Tukysa suppliers in India, which has been supplying genuine life-saving drugs for more than 8 years globally. 

• EFFECT ON FERTILITY

It is advised in females of reproductive potential to use effective contraception during treatment with tucatinib and for at least 1 week after the last dose. 

Male patients are advised with female partners of reproductive potential to use effective contraception during treatment with tucatinib and for at least 1 week after the last dose. 

Based on findings from animal studies, it is found that Tukysa may impair male and female fertility.

• WARNINGS AND PRECAUTIONS

 Diarrhea: Severe diarrhea, including dehydration and acute kidney injury, which could be fatal and cause death, has been reported. It is advised to administer antidiarrheal treatment as clinically indicated. The dose can be interrupted, reduced, or permanently discontinued for TUKYSA based on severity.

Hepatotoxicity: Severe hepatotoxicity has been reported on TUKYSA. Monitoring of ALT, AST and bilirubin before starting TUCATINIB is done every 3 weeks during treatment and as clinically indicated. Interrupt dose, dose reduction, or permanently discontinue TUKYSA based on severity.

 Embryo-Fetal Toxicity: TUKYSA can actively cause fetal harm. It is advised to patients of the potential risk to a fetus and to use effective contraception.

To buy Tukysa online in India, you can call us at +91 9310090915 or visit us at  Indian Pharma Network.

Tukysa The Breakthrough Cancer Drug

INDICATION AND USAGE

Tukysa is a cancer medicine that is a kinase inhibitor. This potent drug is used to treat HER2-positive breast cancer, which is locally advanced or has spread to other parts of the body. This means the cancerous cells produce a protein on their surface, HER2, which stimulates the growth of cancer.

The medicine Tukysa is used with two other medicines, capecitabine, and trastuzumab. It is used after at least two other treatments for HER2-positive cancer have already been given and tried. This efficient drug is within reach in the market, and that too at affordable rates as Tukysa price is economical. 

For more information about the drug, you can call us at +91 9310090915 and ask for further detail regarding Tukysa.

DOSAGE STRENGTH

It is available as yellow, film-coated, oval Tukysa 150 mg tablets and round 50 mg tablets containing tucatinib, its active pharmaceutical ingredient. This drug can only be obtained with a prescription, and treatment should be started and supervised by an expert experienced in giving cancer treatments. 

Tukysa can cause severe hepatotoxicity, and based on the severity of hepatotoxicity, the dose might be interrupted or reduced, and in some cases, it is permanently discontinued. So, the dose must be selected by the doctor only in order to have better and enhanced effects with the least toxicity. 

DOSAGE AND ADMINISTRATION

Tukysa is given orally, that is, by mouth, and the recommended dose is 300 mg twice a day. Patients are also treated with capecitabine and trastuzumab on specific days of a 21-day cycle.

Treatment can continue as long as the cancer does not get worse, there is any progression, and side effects are bearable. The doctor recommends a reduced dose of Tukysa if certain side effects occur, or the treatment may be temporarily or permanently stopped.

 For patients with severe hepatic impairment, taking a dosage of 200 mg orally twice daily is recommended. To know more about Tukysa tablet cost in India, you can visit us at www.indianpharmanetwork.in.

MECHANISM OF ACTION

The active substance in Tukysa is tucatinib. It is a type of cancer medicine called a tyrosine kinase inhibitor. Tucatinib inhibits the phosphorylation of HER2 and HER3, which results in the inhibition of downstream MAPK and AKT signaling and cell proliferation. It showed antitumor activity in HER2-expressing tumor cells by attaching to the HER2 protein on the cancer cells, so its action is blocked. As HER2 helps cancer cells to grow and divide, thus blocking it helps to stop these cells from growing. This causes them to die, controlling the growth of cancer. 

The desired effect can be obtained by taking a certain dose of the drug as recommended by the doctor. To buy Tukysa tablets online at affordable rates, you can visit us or call us at +91 9310090915.

ADVERSE DRUG REACTION

Like any other cancer drug, some Tukysa side effects are accompanied by the ill effects of the drug. The most common side effects associated with Tukysa are nose bleeds, diarrhea, nausea, vomiting, stomatitis which is inflammation of the mouth, rash, arthralgia, palmar-plantar erythrodysesthesia, anemia, increases in the blood levels of liver enzymes ALT and AST and bilirubin, and weight loss. This may affect more than 1 in 10 people using Tukysa.

Other more serious side effects caused due to Tukysa, which are in more than 1 in 20 people using the drug, are diarrhea and increased ALT and AST, hepatotoxicity, nausea, and vomiting may also be serious and can be fatal.

STORAGE

TUKYSA 50 mg and 150 mg tablets are supplied as yellow, film-coated, round, and oval tablets, respectively. Each tablet is debossed with “TUC” on one side and “50” on the other side for 50 mg and “150” in case 150 mg is packaged.

It is stored at a controlled room temperature from 20ºC to 25ºC (68ºF to 77ºF). Dispense to the patient in the original container only. It is stored in the original container to protect it from moisture. The cap should be securely replaced each time after opening. Desiccant needs not be discarded. Once opened, use within 3 months. Discard any unused tablets 3 months after opening the bottle. To seek the price of TUKYSA in India, you can call us at +91 9310090915.

DRUG INTERACTIONS

Although the cost of tucatinib is affordable, it has some following drug interactions that need to be known before using the drug. For more detail, ask your doctor.

Strong CYP3A Inducers or Moderate CYP2C8 Inducers: concomitant use of strong CYP3A inducers or moderate CYP2C8 inducers should be avoided.

Strong CYP2C8 Inhibitors: Avoid concomitant use as it reduces the Tukysa dose if concomitant use cannot be avoided. 

CYP3A Substrates: Avoid co-administering use with CYP3A substrates. As minimal concentration changes may lead to serious or life-threatening toxicities, which can be fatal.

P-gp Substrates: P-gp substrates dose should be reduced, as minimal concentration changes may lead to serious or fatal toxicities.

Enhertu: Dosage and Mechanism of action

INDICATION AND USAGE

For adults with HER2-positive breast cancer, which has spread to other parts of the body or cannot be removed by surgery, ENHERTU is used as prescribed by the doctor. It has proven itself an efficient drug for cancer that is sold at fairly good prices with uncompromised effects. It is available in the market, and anyone with a valid prescription can buy ENHERTU online in India. This effective drug is also given to adults suffering from HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma, which can be metastatic or has spread to other parts of the body. Enhertu is used in patients on its own who have taken one or more HER2-targeted treatments.

DOSAGE AND ADMINISTRATION

ENHERTU is a prescriptive drug that can only be obtained and used under the prescription and supervision of an expert cancer specialist doctor. The drug is available as enhertu 100 mg injection, which comes in lyophilized powder in a single-dose vial for reconstitution.enhertu is given intravenously only without any push or bolus. The recommended dose for HER2-positive breast cancer is 5.4 mg/kg once every 3 weeks of a 21-day cycle. 

For HER2-positive advanced gastric cancer, the recommended dosage of ENHERTU for gastric cancer is 6.4 mg/kg given by dripping the vein once every 3 weeks of a 21-day cycle.

MECHANISM OF ACTION

The active substance in Enhertu is trastuzumab deruxtecan. It is made up of two active components that are linked together. It is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. DXd is a topoisomerase I inhibitor that is small in size and gets attached to the antibody by a cleavable linker. Its binding is followed by HER2 on tumor cells, by lysosomal enzymes, fam-trastuzumab deruxtecan undergoes internalization and intracellular linker cleavage. The membrane-permeable DXd causes DNA damage and apoptotic cell death upon its release.

The FDA approved fam-trastuzumab deruxtecan on August 5, 2022, for use in adult patients with unresectable or metastatic HER2-low breast cancer, and it is available in India. For more details about its mechanism of action and to check for ENHERTU price, you can visit us at Indian Pharma Network, +91 93100 90915.

Trodelvy: A New Era in Cancer Treatment

What is Trodelvy?

TRODELVY is a cancer drug that is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer and locally advanced or metastatic urothelial cancer (mUC). It is a trop-2-directed antibody and topoisomerase inhibitor conjugate drug used at prescribed and recommended doses according to body weight. It is given intravenously only, and the Trodelvy injection price is economical, and it can be bought by any recognized supplier. It is given in the vein by drip on day 1 and day 8 of the repeating 3-week cycle. Treatment may be continued for as long as it remains effective. It has the active ingredient, sacituzumab govitecan, which is responsible for the action of TRODELVY by attaching to the antibody by the linker

Dosage and Administration

It comes as 180 mg lyophilized powder in single-dose vials for reconstitution to be given intravenously. It is given on the basis of weight, and the recommended dose is 10 mg/kg, administered as an IV infusion once weekly. It is also available in 200mg vials, and we supply trodelvy 200 mg vials in Indian against a valid prescription.

Before administering Trodelvy, antipyretic medication is given to the patient to induce nausea and vomiting, which are caused due to an infusion reaction. Antipyretic drugs act as H1 and H2 blockers, and those who have prior infusion reactions are given corticosteroids. After premedication, Trodelvy is given for 3 hours intravenously; during and after 30 minutes, any kind of infusion-related reactions are observed. 

Availability In India

Trodelvy has been compared with standard treatment in one of the main studies, which had 529 patients with metastatic or locally advanced triple-negative breast cancer who received two or more prior systemic (whole-body) treatments, including at least one of them for advanced disease. Patients who took Trodelvy lived for an average of 4.8 months without cancer progression and getting it worse than as compared with 1.7 months for the patients who took standard treatment. Patients on Trodelvy lived for an average of 11.8 months compared with 6.9 months for patients on standard treatment.

Trodelvy is available in India through various generic medication suppliers and the TRODEDLVY injection price in India is pocket-friendly, and anyone with a prescription can purchase it easily.

 Mechanism of action

The active pharmaceutical ingredient in Trodelvy is Sacituzumab govitecan-hziy which consists of two active components that are a monoclonal antibody ( which is a kind of protein ) that has been linked to a small molecule, SN-38. The monoclonal antibody has been made to recognize and attach to Trop-2(a kind of protein in many breast cancer cells). When it is attached, and the drug is used up by the cell, then SN-38 becomes active. SN-38 is a cancer medicine that belongs to the group topoisomerase inhibitors. It blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die. Trodelvy's benefits

are greater than its risks; that's why it is approved by FDA, and anyone with a prescription can buy trodelvy in India.

Adverse Drug Reaction

Like any other medication, it comes with some undesired side effects. The most common side effect caused by taking Trodelvy is diarrhea, Nausea (feeling of being sick), low count of neutrophils( they are a kind of WBC which help to fight against infection), loss of hair which is called alopecia, anemia ( low levels of hemoglobin, causes pale skin and tiredness ). These common ADRs affect more than 1 in 5 people who are undergoing treatment. Other common side effects include loss of appetite, constipation, cough, belly pain, and vomiting. Vomiting and Nausea can also occur during the time of infusion, so to prevent these, antipyretics are given as premedication.

The most common serious side effects are febrile neutropenia which is low white blood cell counts with fever due to infection and diarrhea. Well, this medication is all safe to use and is FDA approved.

Moreover, the cost of Trodelvy in India is economical and budget-friendly, and it should be used under the influence of expert medical supervisors of its specialty.

 Measures to ensure safe and effective use

While preparing in an infusion bag, a sterile syringe is used in order to preserve aseptic practice and make the preparation safe from any kind of contamination. Do not shake, but gently swirl. It is light-sensitive, so it needs to be protected from light and must be stored in cool and shady places. After mixing, if there is any precipitation or cloudy substance forming, don't use the preparation and discard it.

As for all medicines, data on the use of Trodelvy are continuously monitored. Predicted side effects reported with Trodelvy are carefully evaluated, and any necessary action is taken to protect patients. One can ask his pharmacist or healthcare provider for information about trodelvy that is written for health professionals.

During intravenous infusion, too, the patient must be carefully observed. Trodelvy injections are available, and the cost of trodelvy injection is budget friendly as compared to other medications of the same line. For more information and details, Contact us: Indian Pharma Network | Toll-Free:- 1800 889 1064.

The Ultimate Guide to Blincyto

• INDICATION AND USAGE

Blincyto is a cancer drug that has a potent active ingredient, Blinatumomab. It is used to treat B-precursor acute lymphoblastic leukemia, a blood cancer that is called in patients above the age of one year. It is used by those patients whose cancer has relapsed or has not improved with previous treatment. Healthcare professionals uAs part of ‘consolidation therapy,’ to improve the diminution of cancer, Blincyto is used. Its usage is also accompanied in patients who have the protein CD19 on their cancer cells and are ‘Philadelphia-chromosome-negative’ (Ph-negative). It states that the patient’s cancer cells do not have an abnormal Philadelphia chromosome.

Various suppliers can purchase it, and you can also buy Blincyto online from various websites like Indiapharmanetwork. in, Indiamart.com, and more. Indian Pharma Network is among the trusted and most reliable suppliers of generic drugs.

•  Dosage and Preparation

BLINCYTO is available in injections as 35 mcg lyophilized powder that comes in a single-dose vial for administration. Blincyto's price in India is pocket friendly, so it can be easily obtained and only be purchased with a prescription. Treatment should be started by a medical professional with expertise in treating patients with blood cancers. Before initiating the treatment, it is mandatory to measure body weight, as dose calculation is based on weight. A pump device gives it intravenously only by dripping it into the vein.

For reconstitution, the walls of BLINCYTO are added directly with 3 mL of preservative-free Sterile Water for Injection USP, and the resulting final concentration is 12.5 mcg/mL. Gently swirl the prepared infusion avoiding the excess foam.

• Administration

Before administration, check for any particulate matter or discoloration; if observed, the prepared formulation needs to be avoided and should never be used. The prepared infused bag must be continuously induced after 24 or 48 hours of preparation. 

Blincyto is infused continuously for four weeks as part of the treatment cycle. An interval segregates each cycle after a two-week treatment. If the benefits outweigh the risks, patients with no signs of cancer after two cycles are treated with an additional three cycles of BLINCYTO.

The drug is available in India for use. It can be supplied by approved generic and innovative medication suppliers, and We are among the most reliable suppliers to buy  BLINCYTO 38.5 mcg at economical prices. To know more about the drug, contact us at our Toll-free number +91 93100 90915.

• Method of Action 

The active substance in Blincyto is Blinatumomab, an antibody designed to attach to a protein (CD19) found on B cells, including ALL cells because it is a bispecific CD19-directed CD3 T-cell. It also attaches to a protein (CD3) in T cells. The drug is produced in Chinese hamster ovary cells. Attaching to CD3, therefore, acts as a ‘bridge’ that brings T cells and B cells together and causes the T cells to release substances that eventually kill the cancerous B cells.

People with blood cancer can get this medicine against a prescription from any of the suppliers at economical prices as BLINATUMOMAB price is pocket friendly and reasonable in India. 

• Adverse Reactions and Side Effects

It is known that there are specific side effects accompanied by BLINCYTO injection, which can be mild or life-threatening. The most common adverse reactions which are seen after using BLINCYTO are infections, fever, infusion-related reactions, headache, febrile neutropenia, constipation, nausea, diarrhea, vomiting, anemia ( low red blood cell counts), leucopenia (low levels of white blood cell), oedema (swelling because of fluid retention), neutropenia (low levels of neutrophils, a type of white blood cell), thrombocytopenia (low platelet count), blood tests showing changes in liver function, tremor (shaking), back pain, chills, etc.

The most serious reactions associated with BLINCYTO include neutropenia with or without fever, infections, cytokine release syndrome, and tumor lysis syndrome.

• Drug Interactions

There are no as such prior formal drug interaction studies conducted with BLINCYTO. But it is known that starting the treatment of BLINCYTO causes transient release of cytokines that may suppress CYP450 enzymes. Patients with a narrow therapeutic index and receiving concomitant CYP450 substrates during the first 9 days of the first cycle and the first 2 days of the second cycle have the highest drug-drug interaction risk. In these patients, monitor for drug concentrations (e.g., cyclosporine) and toxicity (e.g., warfarin). If needed, adjust the dose of the concomitant drug.

• Use in a specific population

 Pregnancy- From some animal studies, it is found that BLINCYTO may cause fetal harm. When administered to a pregnant woman, it can cause B-cell lymphocytopenia in the fetus according to their action method. But there is no data on the use of BLINCYTO in pregnant women, but due to its capability of crossing the placental barrier shown in animal studies, it is advised to pregnant women not to use it as it may cause potential risk to a fetus. 

It is readily available, and you can buy the product in the market after having a valid prescription and knowing all the side effects. 

Effect on Lactation- There is no information regarding the presence of Blinatumomab which is an active ingredient of BLINCYTO in human milk, but it is advised to mother patients not to breastfeed during and for at least 48 hours after treatment with BLINCYTO.

• STORAGE

BLINCYTO is stored in cold or frozen places, and each package has one BLINCYTO single-dose vial and one intravenous Solution stabilizer. It is mentioned clearly that the IV Solution Stabilizer should not be used to reconstitute BLINCYTO. The original packages are stored and refrigerated at a temperature of 2°C to 8°C (36°F to 46°F), and they should be protected from light until the time of use. It should be stored and transported at 2°C to 8°C (36°F to 46°F) conditions. It is Shipped in packaging that has been validated to maintain the temperature of the contents at 2°C to 8°C (36°F to 46°F).

Storing and transporting BLINCYTO requires an ideal cool temperature, and the Indian pharma network has expertise in cold chains, so the drug is exported more safely and efficiently. We serve our patients the best thing possible,

• DESCRIPTION

The drug is produced in Chinese hamster ovary cells. Blinatumomab contains 504 amino acids with a molecular weight of approximately 54 kilodaltons. Each package of BLINCYTO comprises 1 vial BLINCYTO and 1 vial IV Solution Stabilizer. The drug is supplied in a single-dose vial as a white to off-white lyophilized powder, which is sterile and preservative-free and to be used intravenously. 

Each single-dose vial of BLINCYTO has a 35 mcg drug, and the injection price is comparatively lower and reasonable in the Indian market.  

• Composition

As far as its composition is concerned, it also contains citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. After reconstitution with 3 mL of preservative-free Sterile Water for Injection, the resulting concentration is 12.5 mcg/mL blinatumomab. Intravenous Solution Stabilizer is supplied in a single-dose vial which is sterile, preservative-free, colorless to the slightly yellow, straightforward solution. Citric acid monohydrate (52.5 mg), lysine hydrochloride (2283.8 mg), polysorbate 80 (10 mg), and sodium hydroxide to adjust pH to 7.0, and water for injection are added to each single-dose vial of IV Solution Stabilize.

MEDICATION GUIDE STELARA

•  INDICATION AND USAGE

Stelara is a potent cancer drug with ustekinumab as an active pharmaceutical ingredient. It is used in the treatment of

moderate to severe plaque psoriasis( ps). Red, scaly patches on the skin accompany ps. These are candidates for phototherapy or systemic therapy.

Active psoriatic arthritis. It is inflammation of the joints associated with psoriasis. In this case, Stelara is either given alone or in combination with methotrexate.

Moderately to severely active Crohn’s disease. It is a disease that causes inflammation of the gut. 

Moderately to severely active ulcerative colitis. It is inflammation of the large intestine, causing ulceration and bleeding. 

Stelara is given to adults when their condition has not improved enough with other treatments or an individual cannot receive other treatments. This efficient drug is available in the market, and you can buy STELARA injection online at very economical prices.

• DOSAGE FORMS AND STRENGTH

It comes in different doses for subcutaneous and intravenous infusion. Subcutaneous infusion is available as an injection containing 45 mg/0.5 mL or 90 mg/mL in a single-dose prefilled syringe or 45 mg/0.5 mL in a single-dose vial. Whereas for intravenous infusion, STELARA 130 mg/26 mL (5 mg/mL) solution is available in a single-dose vial injection. Various doses can be obtained against valid prescriptions from any recognized suppliers. 

• DOSAGE AND ADMINISTRATION

There are different doses for plaque psoriasis, Psoriatic Arthritis, and Crohn’s Disease. The recommended doses for these are:

For psoriatic arthritis and plaque psoriasis, if the patient is equal to or less than 100 kgs, then the recommended dose is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. If the patient is above 100 kgs, the recommended dosage is doubled and administered subcutaneously initially and 4 weeks later, followed by 90 mg subcutaneously every 12 weeks.

The drug is given intravenously for Crohn’s disease, and the dose is based on body weight. A body weighing up to 55 kgs, more than 55 kgs, and less than 85 kgs or greater than 85 kgs have doses of 260mg, 390 mg, and 520 mg, respectively. A subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks after that.

Stelara injection cost is economical and can be obtained easily as prescribed by an authorized medical specialist. For more information on Stelara, Contact us: at 9310090915

Blinatumomab (Blincyto®) Overview

•  Availability in India

Blinatumomab is a cancer medicine that is sold under the brand name Blincyto. It is used to treat a blood cancer called B-precursor acute lymphoblastic leukemia in patients of age one year and above. Its usage is accompanied by patients whose cancer has relapsed or has not improved with previous treatment. It can also be used in these patients as part of ‘consolidation therapy’ to improve the diminution of cancer. Blincyto is used in patients who have the protein CD19 on their cancer cells and are ‘Philadelphia-chromosome-negative’ (Ph-negative), which means that the patient’s cancer cells do not have an abnormal chromosome called the Philadelphia chromosome.

It is available in India for use and can be supplied by an approved generic medication supplier.

We are the most reliable suppliers to buy Blincyto 38.5 mcg at economical prices.

•  Dosage Strength and Administration

It can easily be purchased as Blincyto's price in India is pocket friendly and can only be obtained with a prescription, and treatment should be started by a medical specialist who has experience in the treatment of patients with cancers of the blood. It is available in injections as 35 mcg lyophilized powder in a single dose via injection is available for Administration. Before the treatment, body weight is monitored, and the dose is calculated on the basis of weight. It is given by dripping the vein, and the infusion is done intravenously only by a pump device.

For reconstitution, add 3 mL of preservative-free Sterile Water for Injection of USP directly into the walls of BLINCYTO, and the resulting final concentration is 12.5 mcg/mL. The prepared infusion is gently swirled, and excess foam is avoided. If there is any particulate matter or any sort of discoloration is observed, the batch of prepared BLINCYTO must be discarded and should not be used. After preparation, the prepared BLINCYTO-infused bag must be continuously induced over a period of 24 or 48 hours.

For treatment of relapsed or refractory B-precursor ALL, the dose depends on the patient’s weight. Blincyto is infused continuously for four weeks as part of the treatment cycle. Each cycle is separated by an interval after a two-week treatment. Patients are treated with an additional three cycles of BLINCYTO and have no signs of cancer after two cycles if the benefits outweigh the risks for the patient.

It can be obtained from various suppliers, and you can also buy BLINCYTO online from

• Method Of Action

In B-precursor ALL, certain cells that give rise to a type of white blood cell called B cells multiply too quickly, and they eventually replace normal blood cells with abnormal cells. The active substance in Blincyto is blinatumomab which is an antibody that has been designed to attach to a CD19( a protein) found on B cells, including ALL cells. It also attaches to a protein (CD3) in T cells. T cells are another type of white blood cell.

Hence, Blincyto acts as a ‘bridge’, bringing T cells and B cells together. It causes the T cells to release substances that kill the cancerous B cells eventually.

People who have blood cancer of this kind can get this medicine against a prescription from any of the suppliers at economical prices, as the cost of BLINCYTO in India, is budget-friendly.

• Adverse Reactions and Side Effects

BLINCYTO injection can cause some side effects. Most common adverse reactions associated with BLINCYTO are infections, fever, infusion-related reactions, headache, febrile neutropenia, constipation, nausea, diarrhea, vomiting, anemia (low red blood cell counts), edema (swelling because of fluid retention), neutropenia (low levels of neutrophils, a type of white blood cell), leucopenia (low levels of white blood cell), thrombocytopenia (low platelet count), blood tests showing changes in liver function, tremor (shaking), back pain, chills, low blood pressure, low levels of immunoglobulins (antibodies), cytokine release syndrome (a life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure), rapid heartbeat, insomnia (difficulty sleeping), pain in the arms and legs, abdominal (belly) pain, cough and rash.

Most serious reactions associated with BLINCYTO include neutropenia with or without fever, infections, cytokine release syndrome, and tumor lysis syndrome.

Apart from all these side effects, it is very efficient if used properly under the supervision of an expert doctor.

Moreover, BLINCYTO injection price in India is economical, and it can be purchased at reasonable rates. For more detail on the adverse effects of the drug, Call/WhatsApp (+91) 8130290915 or Email us on info@ikrispharmanetwork.com

•  Drug Interactions

There are no formal drug interaction studies that have been conducted with BLINCYTO. Starting the treatment of BLINCYTO causes the transient release of cytokines which may suppress CYP450 enzymes. During the first 9 days of the first cycle and the first 2 days of the second cycle in patients who are receiving concomitant CYP450 substrates, there are the highest drug-drug interaction risk, particularly those with a narrow therapeutic index. In these patients, monitor for toxicity (e.g., warfarin) or drug concentrations (e.g., cyclosporine). Adjust the dose of the concomitant drug as needed.

• USE IN SPECIFIC POPULATION

● Pregnancy- BLINCYTO may cause fetal harm, including B-cell lymphocytopenia, when

administered to a pregnant woman according to their method of action. There is no data on the

use of BLINCYTO in pregnant women, but it is advised to pregnant women not to use it because

it may cross the placental barrier shown in animal studies and may cause potential risks to a fetus.

The background rate of major birth defects and miscarriage is unknown for the indicated

population. It is easily available as you can buy BLINCYTO online, so all the side effects and

use must be understood properly and used in an efficient and safer way.

● Lactation- There is no information regarding the presence of blinatumomab in human milk or the effects on the breastfed infant, or the effects on the production of milk. Because of the fact many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BLINCYTO, including B-cell lymphocytopenia, it is advised to patients not to breastfeed during and for at least 48 hours after treatment with BLINCYTO.

Full restrictions can be seen on the package leaflet. To know more about BLINCYTO price in India you can email us at info@indianpharmanetwork.in

• STORAGE

Each BLINCYTO package contains one BLINCYTO 35 mcg single-dose vial containing a sterile,

preservative-free, white to off-white lyophilized powder and one intravenous Solution stabilizer of 10 mL single-dose glass vial containing a sterile, preservative-free, colorless to a slightly yellow, clear solution. It is clearly mentioned not to use the IV Solution Stabilizer to reconstitute BLINCYTO. BLINCYTO and IV Solution Stabilizer vials in the original package are stored and refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light until the time of use. Do not freeze. Store and transport the prepared intravenous bag containing BLINCYTO solution for infusion at 2°C to 8°C (36°F to 46°F) conditions. Ship in packaging that has been validated to maintain the temperature of the contents at 2°C to 8°C (36°F to 46°F).

Indian pharma network has expertise in cold chains, so the drug is exported in a safer manner and delivered more efficiently. We serve our patients the best thing possible, and to know more about BLINCYTO cost you can visit us at Contact us: Ikris Pharma Network | Toll-Free:- 1800 889 1064

• DESCRIPTION

It is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 and CD3. BLINCYTO is

produced in Chinese hamster ovary cells. It contains 504 amino acids, which have a molecular weight of approximately 54 kilodaltons. Each BLINCYTO package contains 1 vial BLINCYTO and 1 vial IV Solution Stabilizer. BLINCYTO is supplied in a single-dose vial as a sterile, preservative-free, white to off-white lyophilized powder for intravenous Administration. Each single-dose vial of BLINCYTO contains 35 mcg drug, and the Blincyto injection price is pocket efficient. It also contains citric acid monohydrate (3.35 mg), lysine hydrochloride (23.23 mg), polysorbate 80 (0.64 mg), trehalose dihydrate (95.5 mg), and sodium hydroxide to adjust pH to 7.0. After reconstitution with 3 mL of preservative-free Sterile Water for injection, USP, the resulting concentration is 12.5 mcg/mL blinatumomab. IV Solution Stabilizer is supplied in a single-dose vial which is sterile, preservative-free, colorless to a slightly yellow, clear solution.

Each single-dose vial of IV Solution Stabilizer contains citric acid monohydrate (52.5 mg), lysine hydrochloride (2283.8 mg), polysorbate 80 (10 mg), sodium hydroxide to adjust pH to 7.0, and Water for injection. To know more about BLINCYTO price, you can Call/WhatsApp us at (+91 9310090915)